Current Valuation breakdown for AegerionEnterprise Value is a firm valuation proxy that approximates current market value of a company. It is typically used to determine takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that company has on its balance sheet. When takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Aegerion Current Valuation Assessment
In accordance with recently published financial statements Aegerion Pharmaceuticals Inc has Current Valuation of 1.18 B. This is 94.77% lower than that of Healthcare sector, and 99.46% lower than that of Drug Manufacturers - Major industry, The Current Valuation for all stocks is 95.97% higher than the company.
Filter other Stocks by Current Valuation
Aegerion Pharmaceuticals Inc is rated below average in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Drug Manufacturers - Major industry is presently estimated at about 1.29 Trillion. Aegerion adds roughly 1.18 Billion in current valuation claiming only tiny portion of equities under Drug Manufacturers - Major industry.
Follow Aegerion Current Valuation with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Other Aegerion Fundamentals